Moderna shares were trading lower after a Wall Street firm turned bearish on the vaccine maker days after it issued strong quarterly results. HSBC Global Research analysts led by Yifeng Liu downgraded Moderna to Reduce from Hold but raised their price target to $86 from $75 in a Monday report. Moderna stock was down 3.8% to $92.78 in early afternoon trading, while Pfizer another maker of vaccines for Covid-19, was off 2%.
The agency’s vaccine advisory committee could offer clues about an eventual call on how often the vaccines are needed.
The option income strategy gained momentum last week. YieldMax SQ Option Income Strategy ETF (SQY), YieldMax NVDA Option Income Strategy ETF (NVDY) and YieldMax MRNA Option Income Strategy ETF (MRNY) were up in double digits.